Resumé
The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Nuclear Medicine |
| Vol/bind | 60 |
| Udgave nummer | 12 |
| Sider (fra-til) | 1713-1716 |
| Antal sider | 4 |
| ISSN | 0161-5505 |
| DOI | |
| Status | Udgivet - dec. 2019 |
Fingerprint
Citer dette
}
No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy. / Zacho, Helle; Jochumsen, Mads R; Langkilde, Niels C; Mortensen, Jesper C; Haarmark, Christian; Hendel, Helle W; Jensen, Jørgen B; Petersen, Lars J.
I: Journal of Nuclear Medicine, Bind 60, Nr. 12, 12.2019, s. 1713-1716.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
TY - JOUR
T1 - No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy
AU - Zacho, Helle
AU - Jochumsen, Mads R
AU - Langkilde, Niels C
AU - Mortensen, Jesper C
AU - Haarmark, Christian
AU - Hendel, Helle W
AU - Jensen, Jørgen B
AU - Petersen, Lars J
N1 - © 2019 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2019/12
Y1 - 2019/12
N2 - The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.
AB - The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.
U2 - 10.2967/jnumed.119.229062
DO - 10.2967/jnumed.119.229062
M3 - Journal article
C2 - 31147402
VL - 60
SP - 1713
EP - 1716
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 12
ER -